About: Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection
Creator	Zheng, Jenny Matthew, ; Nicol, Melanie Cook, Jack Joshi, Abhay Philip, ; Radojka, ; Rizk, L Sabato, E Savic, M Wesche, David
Source	Medline; PMC
abstract	Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria. To date, these medications are not approved for the treatment of viral infections and there are no well‐controlled, prospective, randomized clinical studies or evidence to support their use in patients with Coronavirus Infectious Disease‐2019 (COVID‐19). Nevertheless, chloroquine and hydroxychloroquine are being studied alone or in combination with other agents to assess their effectiveness in the treatment or prophylaxis for COVID‐19. The effective use of any medication involves an understanding of its pharmacokinetics (PK), safety and mechanism of action. This work provides basic clinical pharmacology information relevant for planning and initiating COVID‐19 clinical studies with chloroquine or hydroxychloroquine, summarizes safety data from healthy volunteer studies, and summarizes safety data from Phase 2 and Phase 2/3 clinical studies in patients with uncomplicated malaria, including a Phase 2/3 study in pediatric patients following administration of azithromycin and chloroquine in combination. In addition, this work presents data describing the proposed mechanisms of action against the severe acute respiratory distress syndrome (ARDS) coronavirus–2 (SARS‐CoV‐2) and summarizes clinical efficacy to date.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1002/cpt.1993
bibo:pmid	32687630
has license	no-cc
sha1sum (hex)	c5338f6783207ef6013b82670ef7567988ff8759
schema:url	https://doi.org/10.1002/cpt.1993
resource representing a document's title	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection
has PubMed Central identifier	PMC7404755
has PubMed identifier	32687630
schema:publication	Clin Pharmacol Ther
resource representing a document's body	covid:c5338f6783207ef6013b82670ef7567988ff8759#body_text
is schema:about of	named entity 'Pharmacokinetics' named entity 'Pharmacological Properties' named entity 'Chloroquine' named entity 'COVID' named entity 'innate immune' named entity 'chloroquine' named entity 'chloroquine phosphate' named entity 'placebo-controlled' named entity 'COVID' named entity 'pediatric' named entity 'nausea' named entity 'inhibitory activity' named entity 'SARS-CoV-2' named entity 'historical data' named entity 'treatment options' named entity 'immunomodulatory' named entity 'chloroquine' named entity 'chemoprophylaxis' named entity 'ECG' named entity 'COVID' named entity 'Hypoglycemia' named entity 'placenta' named entity 'drug-drug interaction' named entity 'Chloroquine' named entity 'follow-up' named entity 'chloroquine' named entity 'precipitant' named entity 'pregnancy' named entity 'AUC' named entity 'placebo' named entity 'chloroquine' named entity 'QTc' named entity 'hydroxychloroquine' named entity 'chloroquine' named entity 'hydroxychloroquine' named entity 'arrhythmia' named entity 'rheumatoid arthritis' named entity 'metabolite' named entity 'extracellular' named entity 'chloroquine' named entity 'effective doses' named entity 'enantiomer' named entity 'infectivity' named entity 'plasma' named entity 'QTc' named entity 'CYP2D6' named entity 'heart rate' named entity 'health care workers' named entity 'precipitant' named entity 'TABLETS' named entity 'pharmacokinetic' named entity 'randomized clinical trials' named entity 'chloroquine' named entity 'hydroxychloroquine' named entity 'cardiac toxicity' named entity 'COVID-19' named entity 'itching' named entity 'skin rashes' named entity 'pre-exposure prophylaxis' named entity 'hepatic disease' named entity 'precipitant' named entity 'chloroquine' named entity 'chloroquine' named entity 'hydroxychloroquine' named entity 'remdesivir' named entity 'hydroxychloroquine' named entity 'chloroquine phosphate' named entity 'hydroxychloroquine' named entity 'intracellular' named entity 'chloroquine' named entity 'enantiomers'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software